Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding

Pan-cancer analysis of whole genomes

(2020)   NATURE

Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) shows efficacy against Osteosarcoma

(2020) Gireesh B Reddy et al.   MOLECULAR CANCER THERAPEUTICS

Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics

(2020) Biancamaria Ricci et al.   eLife

Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

(2019) Kai Shi et al.   World Journal of Surgical Oncology

Tumor metastasis suppressor functions of Ets transcription factor through integrin β3‐mediated signaling pathway

(2019) Mintu Pal   JOURNAL OF CELLULAR PHYSIOLOGY

WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs

(2019) Yuxing Liao et al.   NUCLEIC ACIDS RESEARCH

Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells

(2019) Junbo Liang et al.   FEBS LETTERS

Osteopontin as a multifaceted driver of bone metastasis and drug resistance

(2019) Xiaocong Pang et al.   PHARMACOLOGICAL RESEARCH

Mutant ATRX: uncovering a new therapeutic target for glioma

(2018) Santiago Haase et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling

(2018) Carla Danussi et al.   Nature Communications

NF-κB signaling and integrin-β1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis

(2018) Rui Li et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The Histone Variant H3.3 in Transcriptional Regulation and Human Disease

(2017) Leilei Shi et al.   JOURNAL OF MOLECULAR BIOLOGY

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

The prognostic value of osteopontin in limited-stage small cell lung cancer patients and its mechanism

(2017) Fanglei Liu et al.   Oncotarget

ATRX and DAXX: Mechanisms and Mutations

(2017) Michael A. Dyer et al.   Cold Spring Harbor Perspectives in Medicine

Integrin αvβ3 Signaling in Tumor-Induced Bone Disease

(2017) Kristin Kwakwa et al.   Cancers

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations

(2016) M. Bousquet et al.   ANNALS OF ONCOLOGY

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies

(2016) Geert A. Cirkel et al.   INVESTIGATIONAL NEW DRUGS

Alternative lengthening of telomeres does exist in various canine sarcomas

(2016) Theresa Kreilmeier et al.   MOLECULAR CARCINOGENESIS

New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone

(2016) Hsiao P.J. Voon et al.   NUCLEIC ACIDS RESEARCH

Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis

(2016) Xiaobin Gu et al.   Oncotarget

Leiomyosarcoma With Alternative Lengthening of Telomeres Is Associated With Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome

(2015) Jau-Yu Liau et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Differential nuclear ATRX expression in sarcomas

(2015) Christian Koelsche et al.   HISTOPATHOLOGY

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

(2015) BANU ARUN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

(2015) Jau-Yu Liau et al.   MODERN PATHOLOGY

Systematic discovery of complex insertions and deletions in human cancers

(2015) Kai Ye et al.   NATURE MEDICINE

The role of the transcription factor Ets1 in carcinoma

(2015) Jürgen Dittmer   SEMINARS IN CANCER BIOLOGY

Regulation of osteosarcoma cell invasion through osteopontin modification by miR-4262

(2015) Kun Song et al.   TUMOR BIOLOGY

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

ATRX represses alternative lengthening of telomeres

(2015) Christine E. Napier et al.   Oncotarget

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

(2015) Yuchen Jiao et al.   Oncotarget

Tumor-Selective Response to Antibody-Mediated Targeting of αvβ3 Integrin in Ovarian Cancer

(2015) Charles N. Landen et al.   NEOPLASIA

Decreased Expression of the Chromatin Remodeler ATRX Associates with Melanoma Progression

(2014) Zulekha A. Qadeer et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Role of osteopontin in the pathophysiology of cancer

(2014) Lalita A. Shevde et al.   MATRIX BIOLOGY

Osx-Cre Targets Multiple Cell Types besides Osteoblast Lineage in Postnatal Mice

(2014) Jianquan Chen et al.   PLoS One

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

(2014) Jennifer A. Perry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SB-273005, an antagonist of αvβ3 integrin, reduces the production of Th2 cells and cytokine IL-10 in pregnant mice

(2014) SHAOJUAN WANG et al.   Experimental and Therapeutic Medicine

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes

(2014) Robert Huether et al.   Nature Communications

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

NF- B, an Active Player in Human Cancers

(2014) Y. Xia et al.   Cancer Immunology Research

Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway

(2013) Zhiqiang Zhao et al.   CANCER LETTERS

ETS Transcription Factor ESE1/ELF3 Orchestrates a Positive Feedback Loop That Constitutively Activates NF- B and Drives Prostate Cancer Progression

(2013) N. Longoni et al.   CANCER RESEARCH

The complexity of NF-κB signaling in inflammation and cancer

(2013) Bastian Hoesel et al.   Molecular Cancer

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

The chromatin remodeller ATRX: a repeat offender in human disease

(2013) David Clynes et al.   TRENDS IN BIOCHEMICAL SCIENCES

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

(2012) Courtney A. Lovejoy et al.   PLoS Genetics

Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

(2011) Philip J. Stephens et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

(2010) Peter Hersey et al.   CANCER

Osteopontin expression correlates with invasiveness in cervical cancer

(2009) Jae Yun SONG et al.   AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY

International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons

(2009) Lisa Mirabello et al.   INTERNATIONAL JOURNAL OF CANCER

Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease

(2008) C. R. Walkley et al.   GENES & DEVELOPMENT

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage

(2008) S. D. Berman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA